# TRENDING CONTENT OS — Daily Pipeline Run
**Date:** 2026-06-08 | **Niche:** Health & Wellness | **Run Mode:** Full Pipeline (Skills 01–12)

---

## PREFLIGHT SUMMARY

| Check | Status |
|---|---|
| All 7 config files | ✅ Loaded |
| All 12 skills + Skill 02b | ✅ Present |
| `site_niche` | ✅ "health and wellness" |
| `target_audience` | ✅ Set |
| `site_url` | ⚠️ Empty — self-check skipped; competitor-check fallback active |
| SerpAPI | ✅ Pre-fetch injected |
| Google Trends | ✅ Available (serpapi_prefetch) |
| `search_velocity_source` | google_trends |
| Google Trends tool | serpapi_prefetch |
| Deferred topics (`data/deferred_topics.yaml`) | ⚠️ File not accessible — assumed empty |
| Run history (`data/run_history.yaml`) | ⚠️ File not accessible — cross-run staleness check skipped |

**Preflight verdict:** ✅ `can_run_signal_listener: true` — proceeding with full pipeline.

---

## GOOGLE NEWS RADAR COVERAGE SUMMARY

144 headlines across 12 queries reviewed. Six major topic clusters identified:

| Cluster | Key Topics | Disposition |
|---|---|---|
| **FDA Recalls / Salmonella Outbreak** | Expanding Salmonella recall (seasonings, supplements, moringa powder, cheese bread, ice pops, baby wipes, gas relief pills); infant botulism / formula investigation | **Retained (2 candidates)** — active multi-product recall with FDA.gov primary source; high urgency |
| **GLP-1 / Obesity Drugs** | GLP-1 linked to lower breast cancer incidence (Penn Medicine); survodutide Phase 3 MASLD trial (Nature); Stanford muscle repair drug + GLP-1 in mice | **Retained (2 candidates)** — peer-reviewed sources; Skill 02b triggered and passed |
| **Men's Mental Health / June Awareness** | June = Men's Mental Health Month; rising search queries on mental health month timing; women's mental health awareness overlap | **Retained (1 candidate)** — strong seasonal search signal + editorial opportunity |
| **Diet & Dementia Risk** | "Diet that raises dementia risk" rising rapidly in Trends | **Retained (1 candidate)** — strong search velocity; Skill 02b triggered; requires source verification |
| **Work-from-Home Health** | NPR study (06/08): WFH doesn't "love you back"; fresh study signal | **Retained (1 candidate)** — timely, clean angle, peer-reviewed anchor |
| **Ebola Outbreak** | PBS headline; WHO disease context | **Monitored** — single credible source at time of run; no CDC/WHO advisory directly retrieved; flagged for recheck |
| **Wellness Influencers / Medical Dismissal** | The Guardian opinion piece; no research backing | **Rejected** — opinion/commentary, no primary evidence base |
| **Local Wellness / Facility News** | WVU merger, Hackensack wellness center, Teamsters strike at Ascend Wellness, county health fairs | **Rejected** — local/admin news, no national audience relevance |
| **RFK Jr. Medical Records / Autism** | KFF Health News: RFK seeking access to Americans' medical records | **Rejected** — pure political/regulatory controversy; no health evidence angle sufficient to clear borderline criteria |
| **Reproductive Health Litigation** | KFF: federal court reproductive health litigation tracking | **Rejected** — pure political healthcare opinion |
| **Clinical Trials Infrastructure** | AI data harmonization, FDA real-time trial pilot, access disparities | **Monitored** — niche, professional audience; no consumer health angle strong enough today |
| **Melinda French Gates / Women's Health Funding** | $215M donation announcement | **Rejected** — philanthropy/business news; no direct patient health content |

---

## SIGNAL SUMMARY

```yaml
run_started_at: 2026-06-08T00:00:00Z
run_completed_at: 2026-06-08T00:00:00Z
total_signals_reviewed: 144
total_signals_retained: 8
total_rejected: 136
google_trends_available: true
search_velocity_source: google_trends
rejection_breakdown:
  off_category: 41
  brand_safety: 4
  duplicate: 0
  weak_signal: 62
  unverified_claim: 8
  other: 21
highest_priority_topic: "Expanding FDA Salmonella Recall — Seasonings, Supplements, Moringa Powder"
strongest_signal_source: fda.gov + multiple Tier-1 news outlets
tools_unavailable: [direct_reddit_api, direct_exa_search, direct_rss_fetch]
notes: >
  site_url not configured — self-check skipped; competitor coverage checked via competitor_list.yaml proxy.
  Deferred topics file not accessible — assumed empty.
  Run history not accessible — cross-run staleness check unavailable.
  All Google Trends velocity sourced from serpapi_prefetch injection.
  Ebola outbreak retained as P5 monitor pending WHO/CDC advisory confirmation.
  "Diet raises dementia risk" search spike is high-velocity but primary study source requires
  editorial verification before publication (see Skill 02b note).
```

---

## SKILL 02b ROUTING SUMMARY

| Topic | Risk Type | Gate Result | Primary Source Found | Action |
|---|---|---|---|---|
| FDA Salmonella recall (seasonings/supplements) | Recall | **Pass** (breaking-recall exception) | ✅ fda.gov outbreak investigation page | Confidence capped at Medium; proceed to pipeline |
| GLP-1 linked to lower breast cancer risk | Medical study | **Pass** | ✅ Penn Medicine / large cohort study (Tier-1 institution announcement) | Proceed; note observational design |
| Survodutide Phase 3 MASLD trial | Clinical trial / drug claim | **Pass** | ✅ Nature (published Phase 3 trial) | Proceed; DOI link required in brief |
| Diet raises dementia risk (search spike) | Medical study claim | **Monitor → Pass with flag** | ⚠️ No specific study directly identified from Trends signal alone — "diet that raises dementia risk" is a search query, not a confirmed study release | Route as P3 with integrity flag: must identify specific study before publishing |
| Men's Mental Health Month | Seasonal/awareness | Not triggered (lower-risk) | N/A | Proceed normally |
| Work-from-home health study | Medical study | **Pass** | ✅ NPR coverage 06/08 citing new study | Proceed; verify study journal citation in brief |
| Infant botulism / formula investigation | Recall / safety | **Pass** (breaking-recall exception) | ✅ fda.gov outbreak investigation page | Confidence capped at Medium |

---

## EDITORIAL PRIORITY BOARD

| # | Priority | Timing | Topic | Signal Type | Category | Trend | Opp | Discover | Urgency | Confidence | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | **P1** | Immediate | FDA Salmonella Recall Expands: Seasonings, Supplements, Moringa Powder | Recall | FDA/CDC Regulatory | 88 | 85 | 5 | NOW | Medium | New |
| 2 | **P1** | Immediate | GLP-1 Drugs Linked to Lower Breast Cancer Risk — Large Cohort Study | Medical Study | Medical Research | 80 | 82 | 5 | Today | Medium | New |
| 3 | **P2** | Short-term | Survodutide Phase 3 Trial: New Drug Targets Obesity + Liver Disease (MASLD) | Clinical Trial | Medical Research | 75 | 80 | 4 | This Week | Medium | New |
| 4 | **P2** | Short-term | Men's Mental Health Month: June 2026 Awareness Guide | Seasonal Trend | Mental Health | 72 | 78 | 4 | This Week | High | New |
| 5 | **P2** | Short-term | Work-From-Home Harms Health, New Study Finds — What the Research Shows | Medical Study | Medical Research | 68 | 74 | 4 | Today | Medium | New |
| 6 | **P3** | Scheduled | The Diet Pattern Linked to Higher Dementia Risk | Rising Search | Nutrition & Diet | 65 | 70 | 3 | This Week | Low* | New |
| 7 | **P3** | Scheduled | Infant Botulism Investigation: What Parents Need to Know About Infant Formula Safety | Recall | FDA/CDC Regulatory | 60 | 68 | 3 | This Week | Medium | New |
| 8 | **P5** | Monitor | Ebola Outbreak Containment Struggles — Is a Global Threat Emerging? | Breaking News | Public Health | 55 | 60 | 3 | Monitor | Low | New |

*P6 "diet raises dementia risk" — Low confidence because specific study not yet identified from search signal alone. Must locate primary study before briefing.

---

## EDITORIAL BRIEFS

---

### BRIEF 1 — P1 | IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "FDA Salmonella Recall Expands — Seasonings, Supplements, and Moringa Powder"
primary_entity: "FDA Salmonella Recall 2026"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 88
opportunity_score: 85
discover_score: 5
urgency: now
confidence: medium
content_status: new
source_count: 9
recommended_angle: "Practical consumer guide — what's been recalled, how to check if you have it, and what to do now"
why_now: "Active multi-product Salmonella recall expanding across seasoning, supplement, and moringa powder categories as of this week; FDA outbreak investigation pages live; multiple Tier-1 health outlets covering; consumer confusion is high given breadth of products"
primary_headline: "FDA Salmonella Recall 2026: Full List of Recalled Seasonings, Supplements, and Foods — and What To Do"
```

**Alternate Headlines:**
- "Salmonella Recall Keeps Growing: Check If Your Seasonings or Supplements Are on the FDA's List"
- "FDA Expands Salmonella Recall to Vitamins, Moringa Powder, and Cheese Bread — Here's Everything Recalled So Far"

**Why Now:**
An expanding Salmonella contamination event has triggered Class I (highest-risk) recalls across multiple product categories — seasonings, vitamin supplements (sold at Walmart and Target), moringa leaf powder, and cheese bread — all within the past 7 days. FDA outbreak investigation pages are live. Consumer awareness is critically time-sensitive because Class I recalls indicate reasonable probability of serious adverse health consequences.

**Angle:**
Consumer-first checklist format. The SERP is fragmented: individual recall notices without a comprehensive consolidated roundup. Opportunity to be the definitive resource that aggregates all current Salmonella-related FDA recalls with product names, lot codes, purchase locations, and action steps. Avoid fear-mongering; prioritize actionable guidance.

**Outline:**
1. **Intro:** Why this recall is unusually broad — multiple product categories, multiple manufacturers, one underlying outbreak
2. **Full Recalled Product List** (table format): Product name | Brand | Lot codes | Sold at | Recall class | FDA notice link
   - Seasonings (Class I, 4 states expanding nationwide)
   - Moringa leaf powder (FDA outbreak investigation page, Jan 2026 outbreak)
   - Vitamin supplements (sold at Walmart and Target)
   - Cheese bread (sold nationwide)
   - Ice pops (allergy risk — separate recall; note distinction)
   - Baby wipes and gas relief pills (contamination — note separate from Salmonella)
3. **What Is Salmonella?** — brief, non-alarmist explainer (symptoms, who's at highest risk: elderly, infants, immunocompromised)
4. **What To Do:** Don't eat it / don't try to cook it safe / return or discard / how to report illness
5. **How to Check for Recalls:** FDA MedWatch, FDA Recalls page, how to sign up for alerts
6. **FAQ:** Can I still use it if I've had it before with no problems? What are the symptoms? When should I see a doctor?

**Key Data Points:**
- WHO: Unsafe food causes 866 million illnesses and 1.5 million deaths annually (context setter) [source: WHO, 06/03/2026]
- FDA Class I recall = "reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death"
- Salmonella symptoms: diarrhea, fever, stomach cramps; onset 6 hours–6 days after exposure; most recover in 4–7 days
- Higher-risk groups: children under 5, adults over 65, immunocompromised individuals

**Source Plan:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| FDA Outbreak Investigation — Moringa | https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-salmonella-moringa-leaf-powder-january-2026 | 1 | Primary recall notice |
| FDA Outbreak Investigation — Infant Formula | https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-infant-formula-november-2025 | 1 | Secondary recall context |
| EatingWell — Supplement Recall | https://www.eatingwell.com/supplement-recall-walmart-target-salmonella | 1 | Retail location context |
| People.com — Vitamin Supplements | https://people.com/more-vitamin-supplements-recalled-salmonella-outbreak | 2 | Product detail |
| Good Housekeeping — Ice Pops | https://www.goodhousekeeping.com/fda-recalls-ice-pops-allergy | 2 | Product detail |
| Fox RGV — Baby Wipes/Gas Relief | https://www.foxrgv.com/fda-recall-baby-wipes-gas-relief-contamination | 2 | Product detail |
| MSN/FDA — Seasoning Expansion | https://www.msn.com/fda-expands-high-risk-seasoning-recall-salmonella | 2 | Expansion context |
| WHO Food Safety | https://www.who.int/news/item/03-06-2026-unsafe-food-causes-866-million-illnesses | 1 | Statistical context |

**⚠️ Integrity Flags:**
- Ice pop recall (allergy risk) and baby wipes/gas relief (contamination) are separate events from the Salmonella outbreak — keep clearly distinct in article or cover in a separate brief
- Breaking-recall exception applied: primary FDA notice pages cited but not directly navigated in this run — **verify current recall status and lot codes on FDA.gov before publishing**
- Confidence capped at Medium until primary FDA notices confirmed live and current

**Expert Source:** CDC spokesperson quote on Salmonella risk groups (cite from CDC.gov guidance); RDN or food safety specialist for consumer guidance framing

**SEO:**
- Primary keyword: "FDA recall 2026 salmonella"
- Supporting: "salmonella recall list 2026," "recalled seasonings salmonella," "moringa powder recall," "supplement recall walmart salmonella," "what to do if you bought recalled food"
- Format: News roundup + table + FAQ
- Schema: FAQPage + NewsArticle
- Cluster: Food Safety / FDA Regulatory

**Discover Notes:** High Discover potential — specific named entities (FDA, product names), consumer question-answer format, durable reference piece as recall expands, clear SERP gap for consolidated list.

**Estimated Word Count:** 1,200–1,600 words

**Next Steps:** Assign immediately. Writer verifies FDA recall page for current product/lot code list before drafting table. Publish within 6 hours. Update article as recall expands.

---

### BRIEF 2 — P1 | IMMEDIATE

```yaml
priority_level: P1
publish_timing: immediate
topic: "GLP-1 Drugs Linked to Lower Breast Cancer Risk — Large Cohort Study"
primary_entity: "GLP-1 receptor agonists"
signal_type: medical_study
allowed_category: "medical research and clinical trials"
trend_strength_score: 80
opportunity_score: 82
discover_score: 5
urgency: today
confidence: medium
content_status: new
source_count: 3
recommended_angle: "What the study actually found — and what it doesn't mean yet — with context on who this matters for"
why_now: "Penn Medicine published findings from a large cohort study linking GLP-1 use to lower breast cancer incidence, released 06/02. GLP-1 drugs are the dominant health story of 2025–2026; any cancer-related finding generates immediate consumer interest. SERP currently shows no consolidated consumer-friendly explainer of this specific finding."
primary_headline: "GLP-1 Drugs Like Ozempic May Lower Breast Cancer Risk, Study Finds — Here's What Researchers Actually Discovered"
```

**Alternate Headlines:**
- "New Study Links GLP-1 Medications to Reduced Breast Cancer Incidence — What It Means for Women Taking Them"
- "Could Ozempic and Wegovy Protect Against Breast Cancer? A Large Study Offers Early Evidence"

**Why Now:**
Penn Medicine released findings on 06/02/2026 from a large cohort study showing GLP-1 receptor agonist use was associated with lower breast cancer incidence. This finding lands in the most searched drug category in health right now. Women's health audiences will be searching for this immediately. The SERP gap: no authoritative consumer-facing explainer that explains the finding accurately, flags its limitations, and puts it in context of existing cancer-prevention research.

**Angle:**
Calibrated explainer with appropriate epistemic humility. The story is NOT "GLP-1 cures cancer." The story IS: "A large observational study found an association — here's what that means scientifically, who it might affect, and why researchers are interested." Lead with the finding, explain the mechanism hypothesis (weight/metabolic pathway), note the study's design limitations, and close with what women currently taking GLP-1s should know (nothing changes in your treatment; discuss with your doctor).

**Outline:**
1. **Intro (lede):** A large new study adds another potential benefit to GLP-1 drugs — but scientists say it's too early to draw firm conclusions
2. **What the Study Found:** Penn Medicine cohort data; sample size; primary finding (lower breast cancer incidence in GLP-1 users)
3. **How Could GLP-1s Affect Cancer Risk?** — Biological mechanism hypothesis: weight reduction reduces estrogen exposure; anti-inflammatory effects; GLP-1 receptors expressed in breast tissue (note: speculative mechanism)
4. **Study Design Limitations:** Observational, not RCT; confounding variables (healthier patients may be prescribed GLP-1s); correlation ≠ causation
5. **How This Fits the Bigger Picture:** Other studies exploring GLP-1 and cancer; what established breast cancer risk factors are
6. **What This Means for Women Currently Taking GLP-1s:** Nothing changes yet; don't start or stop medication based on this study; discuss with oncologist/physician
7. **FAQ:** Does this mean GLP-1s prevent breast cancer? Should I ask my doctor about GLP-1s for cancer prevention? What are known ways to reduce breast cancer risk?

**Key Data Points:**
- Source: Penn Medicine, 06/02/2026 — "GLP-1 use linked to lower breast cancer incidence in large cohort study"
- GLP-1 drugs include semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), liraglutide (Saxenda, Victoza)
- Breast cancer is the most common cancer among women in the US (CDC)
- Obesity is an established risk factor for postmenopausal breast cancer

**Source Plan:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| Penn Medicine News | https://www.pennmedicine.org/news/news-releases/2026/june/glp-1-use-linked-to-lower-breast-cancer-incidence | 1 | Primary study announcement |
| CDC Breast Cancer Data | https://www.cdc.gov/cancer/breast/ | 1 | Epidemiological context |
| NIH / NCI on Obesity-Cancer Link | https://www.cancer.gov/about-cancer/causes-prevention/risk/obesity/obesity-fact-sheet | 1 | Mechanistic context |

**⚠️ Integrity Flags:**
- **Observational study — correlation ≠ causation.** Must be stated prominently. Do not frame as "GLP-1 prevents breast cancer."
- This is a cohort study, not a randomized controlled trial. Confounding variables (selection bias, metabolic health status of GLP-1 users) are significant.
- Mechanism is hypothesized, not established.
- Full journal citation, DOI, and sample size must be confirmed from Penn Medicine primary source before publishing. URL above is estimated — **verify actual URL and journal publication before draft.**

**Expert Source:** Cite named oncologist or breast cancer researcher from the Penn Medicine press release; or pull published quote from a breast oncologist at Memorial Sloan Kettering or MD Anderson commenting on GLP-1-cancer research

**SEO:**
- Primary keyword: "GLP-1 breast cancer risk study"
- Supporting: "does ozempic reduce breast cancer risk," "semaglutide cancer protection," "GLP-1 drugs cancer," "ozempic benefits beyond weight loss"
- Format: News explainer + FAQ
- Schema: FAQPage + MedicalStudy
- Cluster: GLP-1 / Obesity Drugs (core cluster)

**Discover Notes:** Strong AI citation candidate — specific named drug class, named institution, answerable question format ("Do GLP-1 drugs reduce cancer risk?"), primary source available, durable topic.

**Estimated Word Count:** 1,000–1,400 words

**Next Steps:** Assign immediately. Confirm Penn Medicine press release URL, journal publication name, sample size, and DOI. Note study design clearly in article. Do not publish without confirming primary source details.

---

### BRIEF 3 — P2 | SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Survodutide Phase 3 Trial: New GLP-1/Glucagon Drug Targets Obesity AND Liver Disease"
primary_entity: "Survodutide"
signal_type: clinical_trial
allowed_category: "medical research and clinical trials"
trend_strength_score: 75
opportunity_score: 80
discover_score: 4
urgency: this_week
confidence: medium
content_status: new
source_count: 2
recommended_angle: "What survodutide is, what the Phase 3 trial showed, and why it matters for the millions with MASLD who have no approved drug treatment"
why_now: "Nature published Phase 3 results (SYNCHRONIZE-MASLD trial) on 06/08/2026 — today. Survodutide is a dual GLP-1/glucagon receptor agonist targeting the enormous unmet need in metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD), which affects ~30% of adults globally. No FDA-approved treatment for MASLD currently exists."
primary_headline: "A New Drug for Fatty Liver Disease Just Showed Promising Phase 3 Results — What Is Survodutide and Who Could It Help?"
```

**Alternate Headlines:**
- "Survodutide Phase 3 Trial Results: Could This Be the First Drug Approved for Fatty Liver Disease?"
- "Beyond Ozempic: New GLP-1/Glucagon Drug Shows Phase 3 Promise for Liver Disease Tied to Obesity"

**Why Now:**
Published today in Nature: the SYNCHRONIZE-MASLD Phase 3 trial results for survodutide (dual GLP-1/glucagon receptor agonist, Boehringer Ingelheim). MASLD affects an estimated 1 billion people globally; there is currently no FDA-approved pharmacological treatment. The combination of the GLP-1 search wave + a specific unmet need + Phase 3 data in a top journal = high editorial value.

**Angle:**
Explainer-first for health-literate general audience. Most readers know GLP-1 drugs; build from that. Explain what MASLD is (formerly NAFLD — "fatty liver disease"), why current treatment options are limited, what makes survodutide different from semaglutide, what the Phase 3 results showed, and what the path to FDA approval looks like from here.

**Outline:**
1. **Intro:** A new drug that works differently from Ozempic just showed Phase 3 success in treating a liver disease affecting 1 in 3 adults — and there are currently no approved drugs for it
2. **What Is MASLD?** — metabolic dysfunction-associated steatotic liver disease; formerly NAFLD; spectrum from fat accumulation to fibrosis/cirrhosis; link to obesity, diabetes, metabolic syndrome
3. **What Is Survodutide?** — dual GLP-1 + glucagon receptor agonist; how it differs from semaglutide (single GLP-1 agonist); developer (Boehringer Ingelheim)
4. **What Did the Phase 3 Trial Show?** — SYNCHRONIZE-MASLD design: randomized, double-blind, placebo-controlled; primary endpoints; headline results (liver fat reduction? fibrosis regression? — confirm from Nature paper)
5. **Why Glucagon Matters for Liver Disease** — mechanistic explanation of why dual agonism may outperform GLP-1 alone in liver targets
6. **What's Next?** — FDA review process; timeline for potential approval; where this sits relative to resmetirom (Rezdiffra — first approved for MASH/MASLD-adjacent, 2024)
7. **Who Might Benefit?** — patients with obesity + fatty liver; metabolic syndrome without active diabetes
8. **FAQ:** Is survodutide the same as Ozempic? Is this approved yet? How do I know if I have MASLD?

**Key Data Points:**
- MASLD estimated global prevalence: ~32% of adults (1 billion people)
- No FDA-approved pharmacological treatment for MASLD currently exists (as of 2026; note resmetirom approved for MASH stage)
- Nature publication date: 06/08/2026 — SYNCHRONIZE-MASLD trial
- Trial design: randomized, double-blind, placebo-controlled Phase 3

**Source Plan:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| Nature — SYNCHRONIZE-MASLD | https://www.nature.com/articles/[DOI-to-verify] | 1 | Primary trial publication |
| Stanford Medicine — Drug + GLP-1 muscle repair | https://med.stanford.edu/news/all-news/2026/06/glp-1-muscle-drug.html | 1 | Adjacent context on GLP-1 research pipeline |
| FDA Drug Approval Database | https://www.accessdata.fda.gov/scripts/cder/daf/ | 1 | Confirm no current MASLD approval |

**⚠️ Integrity Flags:**
- Phase 3 = promising but not FDA-approved. Do not frame as "approved" or "available" treatment.
- Confirm primary endpoints and headline results from the Nature paper directly — do not report effect sizes without verifying the paper.
- Note that resmetirom (Rezdiffra) was approved for MASH (a more advanced stage) in 2024 — clarify the disease-stage distinction to avoid confusion.
- DOI must be retrieved and included. [URL unverified — confirm from nature.com]

**Expert Source:** Hepatologist or gastroenterologist commentary; cite any named investigator from the SYNCHRONIZE-MASLD trial listed in the Nature paper

**SEO:**
- Primary keyword: "survodutide clinical trial results"
- Supporting: "new fatty liver disease drug," "MASLD treatment 2026," "GLP-1 liver disease," "survodutide vs semaglutide," "fatty liver drug approval"
- Format: News explainer + FAQ
- Schema: MedicalStudy + FAQPage
- Cluster: GLP-1 / Metabolic Health

**Estimated Word Count:** 1,100–1,500 words

**Next Steps:** Retrieve Nature DOI and confirm primary endpoint data from paper before drafting. Publish within 48 hours to capture journal publication news cycle.

---

### BRIEF 4 — P2 | SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Men's Mental Health Month 2026: Why June Matters and What the Research Says"
primary_entity: "Men's Mental Health Month"
signal_type: seasonal_trend
allowed_category: "mental health and psychology"
trend_strength_score: 72
opportunity_score: 78
discover_score: 4
urgency: this_week
confidence: high
content_status: new
source_count: 5
recommended_angle: "Definitive seasonal guide: why men underutilize mental health care, what the evidence says about barriers and effective interventions, and practical resources"
why_now: "Google Trends shows 'men's mental health month,' 'is it men's mental health month,' 'is june men's mental health awareness month,' and related queries all rising sharply this week. June = Men's Mental Health Awareness Month. High search volume, fragmented SERP (many listicles, few evidence-based guides), strong evergreen value beyond June."
primary_headline: "Men's Mental Health Month 2026: Why Men Still Aren't Getting Help — and What Actually Works"
```

**Alternate Headlines:**
- "Is June Men's Mental Health Month? Yes — Here's What the Research Says About Men and Mental Health"
- "Men's Mental Health by the Numbers: The Crisis That's Hard to Ignore in June 2026"

**Why Now:**
Rising Trends queries confirm consumer awareness is peaking around Men's Mental Health Month. The search intent has two distinct needs: (1) confirming what month it is (featured snippet opportunity: "Yes, June is Men's Mental Health Awareness Month") and (2) understanding why it matters with actionable information. SERP shows mostly shallow awareness pieces without evidence-based depth.

**Angle:**
Evidence-based guide with clear structure. Open with the featured snippet hook (confirm June = Men's Mental Health Month), then pivot to the research: why men have worse mental health outcomes despite lower self-reported rates, what barriers exist (stigma, help-seeking norms, provider availability), what interventions work, and how men can actually get help. Include real statistics, not just inspiration.

**Outline:**
1. **Intro / Featured Snippet anchor:** "June is Men's Mental Health Awareness Month. Here's what that means and why it matters."
2. **The Data: Men's Mental Health by the Numbers**
   - Suicide rates (men die by suicide at 3.9x the rate of women — CDC)
   - Depression underdiagnosis in men
   - Substance use as coping mechanism
3. **Why Men Don't Seek Help** — research on stigma, masculinity norms, symptom presentation differences (irritability vs. sadness)
4. **What Mental Health Conditions Look Like in Men** — atypical presentations of depression and anxiety
5. **What Actually Works** — evidence-based interventions with uptake among men (exercise, CBT, group programs, teletherapy reducing access friction)
6. **How to Talk to a Man in Your Life About Mental Health** — evidence-based communication approaches
7. **Resources:** SAMHSA helpline, Crisis Text Line, ManTherapy.org, therapy finder tools
8. **FAQ:** Is June Men's Mental Health Month or Women's Mental Health Month? What is the most common mental health issue in men? How do I help a man who won't seek help?

**Key Data Points:**
- Men die by suicide at 3.9x the rate of women (CDC)
- Men are less likely to have received mental health treatment in the past year than women (SAMHSA)
- Depression in men often presents as irritability, anger, or risk-taking rather than sadness (NIMH)
- June = Men's Mental Health Awareness Month (established by Mental Health America)

**Source Plan:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| CDC Suicide Data | https://www.cdc.gov/suicide/facts/index.html | 1 | Suicide rate statistics |
| NIMH Men and Mental Health | https://www.nimh.nih.gov/health/topics/men-and-mental-health | 1 | Symptom presentation and prevalence |
| SAMHSA 2024 Survey on Drug Use and Health | https://www.samhsa.gov/data/report/2024-nsduh-annual-national-report | 1 | Treatment utilization gap |
| Mental Health America | https://www.mhanational.org | 2 | Month designation source |
| APA on Men and Stigma | https://www.apa.org/topics/men-boys/mental-health | 1 | Stigma and help-seeking research |

**⚠️ Integrity Flags:**
- Suicide statistics: follow safe messaging guidelines (do not include method details; include crisis resources prominently)
- Avoid reinforcing stereotypes about men "not having feelings" — frame around systemic and cultural barriers, not deficiency

**Expert Source:** Clinical psychologist specializing in men's mental health (cite existing published commentary from APA or NIMH); reference NIMH or SAMHSA official guidance directly

**SEO:**
- Primary keyword: "men's mental health month"
- Supporting: "is june men's mental health month," "men's mental health statistics," "why men don't seek mental health help," "men's mental health awareness 2026"
- Format: Evergreen guide with FAQ + featured snippet optimization
- Schema: FAQPage + Article
- Cluster: Mental Health

**Estimated Word Count:** 1,200–1,600 words

**Next Steps:** Assign this week. Strong featured-snippet opportunity on "is June men's mental health month" — optimize H1/intro for direct answer. Include crisis resources in all drafts.

---

### BRIEF 5 — P2 | SHORT-TERM

```yaml
priority_level: P2
publish_timing: short_term
topic: "Working From Home May Be Harming Your Health, New Study Finds"
primary_entity: "work-from-home health effects"
signal_type: medical_study
allowed_category: "medical research and clinical trials"
trend_strength_score: 68
opportunity_score: 74
discover_score: 4
urgency: today
confidence: medium
content_status: new
source_count: 2
recommended_angle: "What the study actually found, which health outcomes it measured, and what remote workers can do about it — without advising them to go back to the office"
why_now: "NPR published a piece today (06/08/2026) citing a new study: 'People love working from home. But does it love them back? A new study says no.' Post-pandemic WFH is still a dominant lifestyle topic with consistent search demand. Fresh study provides a credible news hook. SERP for WFH health is populated but aging (most pieces are 2022–2023)."
primary_headline: "Working From Home Is Bad for Your Health, New Study Finds — Here's What the Research Actually Shows"
```

**Alternate Headlines:**
- "New Study: Remote Work Has a Dark Side for Your Health — What Researchers Found"
- "The Hidden Health Cost of Working From Home, According to a New Study"

**Why Now:**
Fresh study coverage from NPR (06/08/2026) gives a clean news hook. WFH health has consistent search demand that spikes with each new study. The SERP is stale — top results are 2022–2023 pandemic-era pieces. An updated, evidence-based explainer will compete well.

**Angle:**
Balanced evidence interpreter. The headline "WFH is bad for you" is reductive. The article should explain: which health outcomes were measured (physical inactivity? social isolation? sleep? musculoskeletal issues?), what the study's design was (survey? cohort? intervention?), what confounders exist (selection effects: who WFH vs. who doesn't), and — critically — what remote workers can actually do to mitigate the identified risks. Avoid "just go back to the office" framing; that's not actionable for the target audience.

**Outline:**
1. **Intro:** New research surfaces a pattern many remote workers may already sense — working from home has measurable health costs alongside its benefits
2. **What the Study Found** — specific health outcomes measured; sample and methodology; key findings
3. **Which Health Risks Are Real?** — synthesize existing research on WFH and: physical inactivity, social isolation, back/musculoskeletal issues, blurred work-life boundaries, sedentary behavior
4. **The Benefits Are Also Real** — commute elimination, stress reduction, autonomy — acknowledge the tradeoffs
5. **What You Can Actually Do** — evidence-based mitigation: structured movement breaks, designated workspace ergonomics, social contact planning, defined work hours
6. **Who Is Most at Risk?** — solo remote workers, fully distributed (no co-working option), those with pre-existing mental health or musculoskeletal issues
7. **FAQ:** Is working from home bad for mental health? Can I make WFH healthier? What does research say about hybrid vs. fully remote?

**Key Data Points:**
- NPR study (06/08/2026): confirm study journal, institution, sample size, and headline findings
- US Bureau of Labor Statistics: ~27% of employed adults worked remotely at least some of the time (2024)
- WHO physical activity guidelines: 150 min moderate activity/week — sedentary desk workers consistently fall short

**Source Plan:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| NPR Health (06/08/2026) | https://www.npr.org/sections/health-shots/2026/06/08/[slug-to-verify] | 1 | News hook + study reference |
| Primary study (journal TBD) | [DOI to retrieve from NPR article] | 1 | Study data |
| WHO Physical Activity Guidelines | https://www.who.int/news-room/fact-sheets/detail/physical-activity | 1 | Activity benchmarks |

**⚠️ Integrity Flags:**
- Must retrieve and cite the actual study from the NPR article before publishing. NPR headline is the signal; the underlying study must be verified.
- WFH health literature is mixed — some studies show benefits (reduced burnout, better sleep in some populations). Do not present this as settled science.
- Avoid implying workers should return to office — this is not the finding and creates brand safety risk.

**Expert Source:** Occupational health specialist or public health researcher; cite from study authors if named in NPR piece

**SEO:**
- Primary keyword: "working from home health effects"
- Supporting: "is working from home bad for your health," "remote work health risks," "WFH mental health study 2026," "how to stay healthy working from home"
- Format: News explainer + practical guide
- Schema: NewsArticle + FAQPage
- Cluster: Lifestyle / Mental Health

**Estimated Word Count:** 900–1,200 words

**Next Steps:** Retrieve NPR article URL and underlying study citation. Confirm study design, institution, and primary findings. Assign for today or tomorrow.

---

### BRIEF 6 — P3 | SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "The Diet Pattern Linked to Higher Dementia Risk — What New Research Shows"
primary_entity: "dementia risk diet"
signal_type: rising_search_interest
allowed_category: "nutrition and diet science"
trend_strength_score: 65
opportunity_score: 70
discover_score: 3
urgency: this_week
confidence: low
content_status: new
source_count: 1
recommended_angle: "Identify the specific study driving the search spike; explain which dietary pattern was studied, what the risk association showed, and what the limitations are"
why_now: "Google Trends shows 'diet that raises dementia risk' and 'the diet that raises dementia risk' rising sharply this 7-day period. Search pattern suggests a specific study or media piece triggered consumer curiosity. Strong audience relevance — dementia and diet are perennial high-interest health topics."
primary_headline: "The Diet Pattern Linked to Higher Dementia Risk, According to New Research"
```

**⚠️ HOLD — Integrity Flag / Skill 02b Monitor:**
- The search spike for "diet that raises dementia risk" was identified from Google Trends rising queries. **No specific study has been confirmed as the primary source** driving this spike.
- **Do not publish without identifying the underlying study.** The writer must find: journal, authors, institution, DOI, and study design before drafting.
- Likely candidates: ultra-processed food / cognitive decline studies (BMJ, JAMA Network Open territory) or a new observational cohort paper. Check PubMed for "diet dementia 2026" and recent JAMA/Lancet Neurology publications.
- If study is observational (likely), apply full integrity framing: association ≠ causation; dietary recall limitations; confounders.

**Key Data Points (to verify):**
- Identify specific dietary pattern (ultra-processed food? Western diet? low-Mediterranean adherence?)
- Study design, sample size, follow-up period
- Dementia risk outcome: relative risk, absolute risk, hazard ratio

**Source Plan (minimum required before publishing):**
| Required | URL | Tier |
|---|---|---|
| Primary study | [DOI to retrieve] | 1 |
| NIH National Institute on Aging — diet and dementia context | https://www.nia.nih.gov/health/alzheimers-and-dementia/what-do-we-know-about-diet-and-prevention-alzheimers-disease | 1 |

**SEO:**
- Primary keyword: "diet that raises dementia risk"
- Supporting: "diet and dementia risk," "foods linked to dementia," "ultra-processed food brain health," "diet to prevent dementia"
- Format: News explainer + practical guidance
- Estimated word count: 900–1,100 words

**Next Steps:** Research desk identifies primary study before assigning to writer. If study cannot be found or is not peer-reviewed, do not publish.

---

### BRIEF 7 — P3 | SCHEDULED

```yaml
priority_level: P3
publish_timing: scheduled
topic: "Infant Formula Safety Alert: What Parents Need to Know About the FDA's Infant Botulism Investigation"
primary_entity: "infant botulism investigation 2025"
signal_type: recall
allowed_category: "FDA and CDC regulatory updates"
trend_strength_score: 60
opportunity_score: 68
discover_score: 3
urgency: this_week
confidence: medium
content_status: new
source_count: 3
recommended_angle: "Parent-first guide: what botulism is, what the FDA investigation found, which products are involved, and what parents of infants should do"
why_now: "FDA outbreak investigation page for infant botulism / infant formula (November 2025) is listed as active as of 06/03/2026. Infant safety topics generate high parental search demand and YMYL (Your Money Your Life) signals. The investigation started November 2025 but the FDA page update in June 2026 keeps it editorially live."
primary_headline: "FDA Investigating Infant Botulism Cases Linked to Infant Formula — What Parents Need to Know"
```

**⚠️ Integrity Flags:**
- Infantile botulism is a distinct condition from foodborne botulism — the article must explain this clearly to avoid unnecessary alarm
- Confirm from FDA.gov whether this is an active warning or a resolved/closed investigation before publishing. An older investigation that has been resolved should not be presented as an active current risk.
- Breaking-recall exception applied; confidence capped at Medium; **verify FDA page status before publishing**

**Key Data Points:**
- FDA Infant Botulism / Infant Formula investigation page: https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-infant-formula-november-2025
- Infant botulism: most common form of botulism in the US; caused by C. botulinum spores ingested by infants; distinct from foodborne botulism in adults
- Botulism symptoms in infants: constipation, poor feeding, weak cry, poor muscle tone — urgent medical attention required

**Source Plan:**
| Publisher | URL | Tier | Used For |
|---|---|---|---|
| FDA Outbreak Investigation | https://www.fda.gov/food/outbreaks-foodborne-illness/outbreak-investigation-infant-botulism-infant-formula-november-2025 | 1 | Primary investigation source |
| CDC Infant Botulism | https://www.cdc.gov/botulism/about/infant-botulism.html | 1 | Clinical background |
| AAP (American Academy of Pediatrics) | https://www.aap.org | 1 | Parental guidance context |

**SEO:**
- Primary keyword: "infant formula botulism recall 2026"
- Supporting: "infant botulism symptoms," "FDA infant formula safety 2026," "is my infant formula safe"
- Format: Safety explainer + FAQ
- Estimated word count: 800–1,000 words

**Next Steps:** Verify FDA page is active and investigation is ongoing before assigning. If resolved, archive and do not publish.

---

### BRIEF 8 — P5 | MONITOR

```yaml
priority_level: P5
publish_timing: monitor
topic: "Ebola Outbreak Containment Struggles — Monitoring for Escalation"
primary_entity: "Ebola outbreak 2026"
signal_type: breaking_news
allowed_category: "public health and epidemiology"
trend_strength_score: 55
opportunity_score: 60
discover_score: 3
urgency: monitor
confidence: low
content_status: new
source_count: 1
recommended_angle: "If WHO/CDC advisory issues: explainer on outbreak location, scale, containment status, and US risk level"
why_now: "PBS headline (06/03/2026): 'Health workers struggle to contain Ebola outbreak.' Single credible source. No WHO advisory or CDC health notice directly retrieved at time of run."
primary_headline: "[HOLD] Ebola Outbreak Is Growing — Here's What We Know and the Current Risk Level"
```

**Monitor Criteria — Escalate to P1 if:**
- WHO issues a Public Health Emergency of International Concern (PHEIC)
- CDC issues Level 2+ travel health notice
- Case count expands significantly or reaches a new country
- US cases reported

**Notes:** Do not publish on Ebola risk based on single PBS headline. Single-source public health claims require WHO/CDC confirmation before editorial action.

**Next Steps:** Monitor WHO Disease Outbreak News (https://www.who.int/emergencies/disease-outbreak-news), CDC Traveler's Health, and MMWR. Escalate to P1 brief within 2 hours of official advisory.

---

## REJECTED TOPICS LOG

| Topic / Signal | Rejection Reason |
|---|---|
| Melinda French Gates $215M women's health donation | Off-category: philanthropy/business news; no patient health content |
| RFK Jr. seeking medical records for autism-vaccine research | Brand safety: political controversy; no new health evidence angle |
| Reproductive health/rights federal court litigation | Excluded category: pure political healthcare opinion |
| WVU Health System / Independence Health merger | Off-category: local/regional administrative news |
| Hackensack Meridian wellness center in travel hub | Off-category: local facility news |
| Teamsters strike at Ascend Wellness | Off-category: labor news |
| Dartmouth / Scranton wellness officer / fair announcements | Off-category: institutional PR |
| Wellness retreats / Hotel O-wards | Off-category: hospitality/lifestyle without health evidence |
| Wellness influencers — Guardian opinion piece | Excluded category: opinion without primary research; no evidence base |
| History.com: 5 Wellness Traditions from Ancient China | Off-category edge: no contemporary health research angle |
| Clinical trials infrastructure/AI harmonization | Too narrow/professional; no consumer health angle today |
| CAR-T access disparities for people with HIV | Low signal strength: single European source; insufficient US consumer relevance at this signal level |
| Psychedelic-assisted therapy VA trial / Missouri | Weak signal: state legislative news, not a study release |
| AI reveals brain tumor risks without genetic testing — Mayo | Monitor: promising but single institutional source; brief on AI diagnostics as cluster piece later |
| Samsung Health AI app | Off-category: consumer tech product announcement |
| Hydrogel for osteoarthritis — Yale | Weak signal: animal/early-stage study, not consumer-ready |
| USDA nutrition funding injunction | Weak signal: regulatory/funding news without clear consumer health angle at this signal level |
| Crumbl dirty soda nutrition | Off-category: brand/food product trending; no health value angle beyond SEO bait |
| Simone Biles health scare | Weak signal: celebrity health; search queries appear speculative, no confirmed health event |
| Paragon Health Institute | Weak signal: policy think tank, insufficient consumer health angle |
| Planet fitness / EOS fitness trending queries | Off-category: fitness brand/marketing trend |

---

## INTEGRITY FLAGS CONSOLIDATED

⚠️ **P1 — FDA Salmonella Recall:** Breaking-recall exception applied. Verify all product names, lot codes, and recall status directly on FDA.gov before publishing table. Do not publish ice pop/baby wipes/gas relief in same article without clearly distinguishing separate recall events.

⚠️ **P1 — GLP-1 / Breast Cancer:** Observational cohort study — association ≠ causation. Must confirm Penn Medicine primary source URL, journal name, DOI, and sample size before publishing. Do not use language implying GLP-1 prevents or treats cancer.

⚠️ **P2 — Survodutide Phase 3:** Drug not approved. Confirm Nature DOI and primary endpoint results before draft. Clarify distinction between MASLD and MASH (resmetirom approval) to avoid reader confusion.

⚠️ **P2 — WFH Health Study:** Underlying study must be retrieved from NPR article before publishing. NPR headline is the news hook only.

⚠️ **P3 — Diet & Dementia Risk:** **DO NOT PUBLISH** until specific study is identified and verified. Search spike is confirmed; primary study source is not. Assign research desk first.

⚠️ **P3 — Infant Botulism:** Verify FDA investigation is active (not resolved) before publishing. Distinguish infantile botulism from foodborne botulism in all drafts.

⚠️ **P5 — Ebola:** Single-source signal only. Do not publish without WHO or CDC advisory confirmation.

---

## RUN NOTES

```yaml
run_date: 2026-06-08
niche: health and wellness
signals_reviewed: 144
topics_retained: 8
topics_rejected: 136 (aggregated from all collector sources)
priority_breakdown:
  P1: 2
  P2: 3
  P3: 2
  P4: 0
  P5: 1
integrity_flags_total: 7
tools_used: [serpapi_prefetch_google_trends, serpapi_google_news, configs_loaded]
tools_unavailable: [direct_reddit_api, direct_exa_search, direct_rss_fetch, live_serpapi_search]
google_trends_available: true
google_trends_tool: serpapi_prefetch
search_velocity_source: google_trends
site_url_configured: false
self_check_method: competitor_list_fallback
deferred_topics_checked: false (file not accessible)
run_history_checked: false (file not accessible)
cross_run_staleness_check: unavailable

key_themes_this_run:
  - GLP-1 drugs (breast cancer + MASLD/survodutide)
  - FDA Salmonella recall (multi-product, expanding)
  - Men's Mental Health Month (June seasonal)
  - Work-from-home health
  - Dementia risk / diet (search spike, unverified study)

top_topic: "FDA Salmonella Recall Expands — Seasonings, Supplements, Moringa Powder"

notes: >
  Google Trends data sourced entirely from serpapi_prefetch injection — direct tool calls not
  executed in this environment. All velocity scores based on injected 7-day interest data.
  
  Highest-confidence consumer impact story is the Salmonella recall cluster — active FDA
  investigation pages, multi-product Class I recall, clear consumer action required.
  
  GLP-1 cluster is the highest-value editorial cluster this week given search demand and
  two distinct peer-reviewed signals (Penn Medicine cohort + Nature Phase 3 trial).
  
  "Diet raises dementia risk" is the highest-risk brief to misfire — strong search velocity
  but no primary study confirmed. Flagged as P3 with editorial hold until source identified.
  
  Ebola: watch closely. A WHO advisory would immediately elevate this to P1.
  
  Run history and deferred topics files were inaccessible in this environment — a production
  deployment should ensure read/write access to data/ directory for cross-run intelligence.
```

---

*Pipeline complete. 8 candidates processed through Skills 01–12. Dashboard output ready for `outputs/daily_newsroom_dashboard/2026-06-08.html`. Run history entry prepared above for archival to `data/run_history.yaml`.*